Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap

JACC Heart Fail. 2017 Jun;5(6):460-463. doi: 10.1016/j.jchf.2017.03.007.

Authors

Antonio L Perez¹, Veraprapas Kittipibul¹, W H Wilson Tang¹, Randall C Starling²

Affiliations

¹ Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
² Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: starlir@ccf.org.

PMID: 28571599
DOI: 10.1016/j.jchf.2017.03.007

No abstract available

Keywords: Food and Drug Administration; guidelines; heart failure; heart failure with reduced ejection fraction; sacubitril/valsartan.

Publication types

Review

MeSH terms

Aminobutyrates / therapeutic use*
Angiotensin Receptor Antagonists / therapeutic use
Biphenyl Compounds
Drug Approval*
Drug Combinations
Heart Failure / drug therapy*
Humans
Tetrazoles / therapeutic use*
United States
United States Food and Drug Administration*
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Valsartan
sacubitril and valsartan sodium hydrate drug combination